TD Asset Management Inc Acquires 19,121 Shares of Bausch Health Companies Inc. (NYSE:BHC)

TD Asset Management Inc raised its holdings in Bausch Health Companies Inc. (NYSE:BHCFree Report) by 1.7% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,156,368 shares of the company’s stock after acquiring an additional 19,121 shares during the quarter. TD Asset Management Inc owned approximately 0.32% of Bausch Health Companies worth $9,322,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently bought and sold shares of the business. Goldentree Asset Management LP lifted its holdings in shares of Bausch Health Companies by 19.6% in the 3rd quarter. Goldentree Asset Management LP now owns 23,987,462 shares of the company’s stock worth $197,177,000 after buying an additional 3,931,234 shares during the period. Nomura Holdings Inc. lifted its holdings in shares of Bausch Health Companies by 67.7% in the 3rd quarter. Nomura Holdings Inc. now owns 18,086,000 shares of the company’s stock worth $148,667,000 after buying an additional 7,303,015 shares during the period. Hudson Bay Capital Management LP lifted its holdings in shares of Bausch Health Companies by 35.3% in the 3rd quarter. Hudson Bay Capital Management LP now owns 11,500,000 shares of the company’s stock worth $94,530,000 after buying an additional 3,000,000 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Bausch Health Companies by 1.6% in the 3rd quarter. Vanguard Group Inc. now owns 11,487,768 shares of the company’s stock worth $94,429,000 after buying an additional 175,489 shares during the period. Finally, Mizuho Markets Americas LLC purchased a new stake in shares of Bausch Health Companies in the 3rd quarter worth $57,540,000. Institutional investors own 78.65% of the company’s stock.

Bausch Health Companies Price Performance

Shares of NYSE BHC opened at $6.20 on Wednesday. The stock has a market capitalization of $2.27 billion, a P/E ratio of -5.00 and a beta of 0.83. Bausch Health Companies Inc. has a 1-year low of $6.09 and a 1-year high of $11.46. The business has a fifty day moving average price of $8.15 and a 200 day moving average price of $8.18.

Bausch Health Companies (NYSE:BHCGet Free Report) last released its quarterly earnings results on Thursday, May 2nd. The company reported $0.59 EPS for the quarter, missing analysts’ consensus estimates of $0.75 by ($0.16). Bausch Health Companies had a negative net margin of 5.07% and a negative return on equity of 2,370.91%. The business had revenue of $2.15 billion during the quarter, compared to analysts’ expectations of $2.18 billion. As a group, equities research analysts anticipate that Bausch Health Companies Inc. will post 3.63 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have weighed in on BHC. Jefferies Financial Group lowered their target price on Bausch Health Companies from $16.00 to $14.00 and set a “buy” rating for the company in a report on Tuesday, February 20th. StockNews.com upgraded Bausch Health Companies from a “hold” rating to a “buy” rating in a report on Wednesday, May 15th. Piper Sandler upped their price objective on Bausch Health Companies from $7.00 to $9.00 and gave the stock a “neutral” rating in a research note on Monday, April 29th. Finally, Royal Bank of Canada decreased their price objective on Bausch Health Companies from $12.00 to $11.00 and set a “sector perform” rating for the company in a research note on Tuesday, April 23rd. Three analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $11.33.

View Our Latest Stock Analysis on BHC

Bausch Health Companies Company Profile

(Free Report)

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.

See Also

Want to see what other hedge funds are holding BHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bausch Health Companies Inc. (NYSE:BHCFree Report).

Institutional Ownership by Quarter for Bausch Health Companies (NYSE:BHC)

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.